Recent advances in vaccine adjuvants: The development of MF59 emulsion and polymeric microparticles

Molecular Medicine Today

Volumn 3, Issue 2, 1997, Pages 69-75

  O'Hagan, Derek T ^a   Ott, Gary S ^a   Van Nest, Gary ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN;

ANTIGEN SPECIFICITY; CONTROLLED RELEASE FORMULATION; DRUG POTENCY; DRUG SAFETY; GENE TECHNOLOGY; IMMUNOGENICITY; IMMUNOSTIMULATION; MICROEMULSION; REVIEW; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BIOPOLYMERS; BIOTECHNOLOGY; HUMANS; IMMUNITY, MUCOSAL; POLYSORBATES; SQUALENE; VACCINES, SYNTHETIC;

EID: 0031062313     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(96)10058-7     Document Type: Review

References (47)

1. 1 Plotkin, S. and Mortimer, E.A. (1988) Vaccines, W.B. Saunders
2. 2 Powell, M. and Newman, M. (1995) Design considerations for subunit vaccines, in Vaccine Design: the Subunit and Adjuvant Approach (Powell, M. and Newman M., eds), pp. 1-28, Plenum
3. 3 Schirmbeck, R., Melber, K., Mertens, T. and Reimann, J. (1994) Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) antigen in mice: implication for the pathogenesis of HBV-induced hepatitis, J. Virol. 68, 1418-1425
4. 4 Gupta, R.K., Rost, B.E., Relyveld, E. and Siber, G.R. (1995) Adjuvant properties of aluminium and calcium compounds, in Vaccine Design: the Subunit and Adjuvant Approach (Powell, M. and Newman, M., eds), pp. 229-242, Plenum
5. 5 Gupta, R.K. et al. (1993) Adjuvants - a balance between toxicity and adjuvan-ticity, Vaccine 10, 96-97
6. 6 Ott, G., Van Nest, G. and Burke, R.L. (1992) The use of muramyl peptides as vaccine adjuvants, in Vaccine Research and Development (Koff, W. and Six, H.R., eds), pp. 89-114, Marcel Dekker
7. 7 Myers, K.R. and Snyder, D.S. (1992) Detailed composition of natural MPL® immunostimulant, J. Cell Biochem. (Abstr suppl.) 16C, CB112
8. 8 Ulrich, J.T. and Ulrich, K.R. (1995) Monophosphoryl lipid A as an adjuvant: past experiences and new directions, in Vaccine Design: the Subunit and Adjuvant Approach (Powell, M. and Newman. M., eds), pp. 495-524, Plenum
9. 9 Kensil, C.R. et al. (1992) Structure/function relationship in adjuvants from Quillaja saponaria Molina, in Vaccines 92 (Brown, E, Channock, R.M., Ginsberg, H.S. and Lerner, R.A., eds), pp. 35-40, Cold Spring Harbor Laboratory Press
10. 10 Livingston, P.O. et al. (1994) Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma, Vaccine 12, 1275-1280
11. 11 Gregoriadis, G. (1990) Immunological adjuvants: a role for liposomes, Immunot. Today 11, 89-97
12. 12 Alving, C.R. (1992) Immunologic aspects of liposomes, presentation and processing of liposomal protein and phospholipid antigens, Biochim. Biophys. Acta 1113, 307-322
13. 13 Bengtsson, K.L. and Sjölander, A. (1996) Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant, Vaccine 14, 753-760
14. 14 Allison, A.C. and Byars, N.E. (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity, J. Immunol. Methods 95, 157-168
15. 15 Ott, G., Barchfeld, G. and van Nest, G. (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59, Vaccine 13, 1557-1562
16. 16 Ott, G. et al. (1995) MF59: design and evaluation of a safe and potent adjuvant for human use, in Vaccine Design: the Subunit and Adjuvant Approach (Powell, M. and Newman M., eds), pp. 277-294, Plenum
17. 17 Couch, R.B. (1993) Advances in influenza virus vaccine research, Ann. New York Acad. Sci. 685, 803-812
18. 18 Langenberg, A.G.M. et al. (1995) A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity, Ann. Intern. Med. 122, 889-898
19. 19 Kahn, J.O. et al. (1994) Clinical and immunologic responses to human immuno-deficiency virus (HIV) type I SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidyl-ethanolamine in non HTV-infected human volunteers, J. Infect. Dis. 170, 1288-1291
20. 20 Wang, J.B. et al. (1996) Mucosal antibodies to human cytomegalovirus glycoprotein b occur following both natural infection and immunization with human cytomegalovirus vaccines, J. Infect. Dis. 174, 387-392
21. 21 Valensi, J.M., Carlson, J.R. and Van Nest, G. (1994) Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants, J. Immunol. 153, 4029-4039
22. 22 O'Hagan, D.T. (1994) Microparticles as oral vaccines, in Novel Delivery Systems for Oral Vaccines (O'Hagan, D.T., ed.), pp. 175-205, CRC Press
23. 23 Tabata, Y. and Ikada, Y. (1990) Phagocytosis of polymer microspheres by macrophages, Adv. Polym. Sci. 94, 107-114
24. 24 Wise, D.L., Fellman, T.D, Sanderson, J.E. and Wentworth, R.L. (1979) Lactide/glycolide polymers used as surgical suture material, raw material for osteosynthesis and in sustained release of drugs, in Drug Carriers in Medicine (Gregoriadis, G., ed.), pp 237-270, Academic Press
25. 25 Maulding, H.V. (1987) Prolonged delivery of peptides by microcapsules, J. Cont. Rel. 6, 167-176
26. 26 O'Hagan, D.T. et al. (1991) Biodegradable microparticles as controlled release antigen delivery systems, Immunology 73, 239-242
27. 27 Eldridge, J.H. et al. (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies, Infect. Immun. 59, 2978-2986
28. 28 O'Hagan, D.T. et al. (1993) Long term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles, Vaccine 11, 965-969
29. 29 O'Hagan, D.T. et al. (1991) Controlled release microparticles for vaccine development, Vaccine 9, 768-771
30. 30 Maloy, K.J., Donachie, A.M., O'Hagan, D.T. and Mowat, A.M. (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles, Immunology 81, 661-667
31. + Th1 cells, Vaccine 13, 1741-1749
32. 32 Singh, M., Singh, O., Singh, A. and Talwar, G.P. (1992) Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres, Int. J. Pharm. 85, R5-R8
33. 33 O'Hagan, D.T. et al. (1995) The preparation, characterization and pre-clinical evaluation of an orally administered HIV-1 vaccine, consisting of a branched synthetic peptide immnnogen entrapped in controlled release microparticles, J. Cont. Rel. 36, 75-84
34. 34 Cleland, J.L. et al. (1994) Development of a single-shot subunit vaccine for HIV-1, AIDS Res. Hum. Retroviruses 10, S21-S26
35. 35 Eldridge, J.H. et al. (1991) Controlled vaccine release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches, J. Cont. Rel. 11, 205-214
36. 36 Challacombe, S.J. et al. (1992) Enhanced secretory IgA and systemic IgG after oral immunization with biodegradable microparticles, Immunology 76, 164-168
37. 37 Jones, D.H. et al. (1996) Oral immunization with microencapsulated pertussis fimbriae induces protective immunity in mice, Infect. Immun. 64, 489-494
38. 38 Cahill, E.S. et al. (1995) Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin, Vaccine 13, 455-462
39. 39 Shahin, R. et al. (1995) Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres, Infect. Immun. 63, 1195-1200
40. 40 Yan, C. et al. (1995) Intranasal immunization with ricin toxoid (RT) vaccine encapsulated in polymeric microspheres against aerosol challenge, Proc. Int. Symp. Cont. Rel. Bioact. Mater. 22, 39-40
41. 41 Marx, P.A. et al. (1993) Protection against vaginal SIV transmission with microencapsulated vaccine, Science 260, 1323-1327
42. 42 Tseng, J. et al. (1995) Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres, Infect. Immun. 63, 2880-2885
43. 43 Zhou, F., Kraehenbuhl, J-P. and Neutra, M.R. (1995) Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes, Vaccine 13, 637-644
44. 44 Pizza, M. et al. (1994) Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14, 51-60
45. 45 Di Tommaso, A. et al. (1996) Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat labile enterotoxin as a mucosal adjuvant, Infect. Immun. 64, 974-979
46. 46 Johnson, O.L. et al. (1996) A month-long effect from a single injection of microencapsulated human growth hormone, Nat. Med. 2. 795-799
47. 47 Kato, T. and Owen, R.L. (1994) Structure and function of intestinal mucosal epithelium, in Handbook of Mucosal Immunology (Ogra, P.L. et al., eds.), pp. 11-26, Academic Press